In cancer diagnosis, methylation biomarkers are used to detect early-stage cancers and to monitor disease progression. For example, the methylation status of the promoter region of the MGMT gene is used to predict the response to alkylating agents in glioblastoma. Similarly, hypermethylation of the BRCA1 and BRCA2 genes can indicate a predisposition to breast and ovarian cancers.
